Abstract Details
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Bradford Dickerson, MD, FAAN | Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arkuda. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lantheus. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Dickerson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Dickerson has received publishing royalties from a publication relating to health care. Dr. Dickerson has received publishing royalties from a publication relating to health care. |
| No disclosure on file | |
| Charles R. Guttmann | Charles R.G. Guttmann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sintetica SA. Charles R.G. Guttmann has received stock or an ownership interest from Alnylam. Charles R.G. Guttmann has received stock or an ownership interest from Roche. Charles R.G. Guttmann has received stock or an ownership interest from Novartis. Charles R.G. Guttmann has received stock or an ownership interest from Arrowhead Pharmaceuticals. Charles R.G. Guttmann has received stock or an ownership interest from Protalix. Charles R.G. Guttmann has received stock or an ownership interest from Promethee. Charles R.G. Guttmann has received stock or an ownership interest from GSK. Charles R.G. Guttmann has received stock or an ownership interest from Sangamo. Charles R.G. Guttmann has received stock or an ownership interest from Alcon. Charles R.G. Guttmann has received stock or an ownership interest from Cocrystal Pharma. The institution of Charles R.G. Guttmann has received research support from NIH. The institution of Charles R.G. Guttmann has received research support from McGill University. The institution of Charles R.G. Guttmann has received research support from National Multiple Sclerosis Society. The institution of Charles R.G. Guttmann has received research support from BrightFocus Foundation. The institution of Charles R.G. Guttmann has received research support from National Multiple Sclerosis Society. The institution of Charles R.G. Guttmann has received research support from University of Connecticut Health Center. The institution of Charles R.G. Guttmann has received research support from U.S. Office of Naval Research. |
| Ronald J. Killiany, PhD (Boston University School of Medicine) | Dr. Killiany has nothing to disclose. |